JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on March 29, 2004; DOI: 10.1124/jpet.104.066886


0022-3565/04/3102-488-497$20.00
JPET 310:488-497, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.066886v1
310/2/488    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hess, J. F.
Right arrow Articles by Pettibone, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hess, J. F.
Right arrow Articles by Pettibone, D. J.

CELLULAR AND MOLECULAR

Generation and Characterization of a Human Bradykinin Receptor B1 Transgenic Rat as a Pharmacodynamic Model

J. Fred Hess, Richard W. Ransom, Zhizhen Zeng, Raymond S. L. Chang, Patricia J. Hey, Lee Warren, Charles M. Harrell, Kathryn L. Murphy, Tsing-Bau Chen, Patricia J. Miller, Edward Lis, Duane Reiss, Raymond E. Gibson, M. Kristine Markowitz, Robert M. DiPardo, Dai-Shi Su, Mark G. Bock, Robert J. Gould, and Douglas J. Pettibone

Departments of Molecular Neurology (J.F.H, R.W.R., P.J.H., L.W., C.M.H., K.L.M., T.-B.C., P.J.M., E.L., D.R., D.J.P), Imaging (Z.Z., R.S.L.C., R.E.G), Medicinal Chemistry (M.K.M., R.M.D., D.-S.S., M.G.B), and Biomedical Research (R.J.G.) Merck Research Laboratories, West Point, Pennsylvania

Antagonists of the B1 bradykinin receptor (B1R) offer the promise of novel therapeutic agents for the treatment of inflammatory and neuropathic pain. However, the in vivo characterization of the pharmacodynamics of B1R antagonists is hindered by the low level of B1R expression in healthy tissue and the profound species selectivity exhibited by many compounds for the human B1R. To circumvent these issues, we generated a transgenic rat expressing the human B1R under the control of the neuron-specific enolase promoter. Membranes prepared from whole brain homogenates of heterozygous transgenic rats indicate a B1R expression level of 30 to 40 fmol/mg; there is no detectable B1R expression in control nontransgenic rats. The pharmacological profile of the B1R expressed in the transgenic rat matches that expected of the human, but not the rat receptor. The mapping of the transgene insertion site to rat chromosome 1 permitted the development of a reliable assay for the identification of homozygous transgenic rats. Significantly, homozygous transgenic rats express 2-fold more B1R than heterozygous animals. Autoradiographic analyses of tissue sections from transgenic rats reveal that the B1R is broadly expressed in both the brain and spinal cord. The human B1R expressed in the transgenic rat functions in an in vitro contractile assay and thus has the potential to elicit a functional response in vivo. Using the humanized B1R transgenic rat, an assay was developed that is suitable for the routine evaluation of a test compound's ability to occupy the human B1R in the central nervous system.


Received February 12, 2004; accepted March 29, 2004.

Address correspondence to: Dr. J. Fred Hess, Merck Research Lab, WP26A-3000, P.O. Box 4, West Point PA 19486. E-mail: fred_hess{at}merck.com







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.